Oncology Brothers shared a post on X:
“Day 1 ASCO26 highlights:
- CROWN (update): ALK+ NSCLC
- OptiTROPLung05: SacTMT/IO NSCLC
- WuKONG28: EGFR 20 NSCLC
- EV302 (update): EV-Pembro mUC
- MajesTEC9: Teclistamab in RRMM 6. SUCCESSOR2: Mezigdomide in RRMM
CROWN (7yrs Update): PhIII, n= 296, Lorlatinib vs. Crizotinib ALK+ mNSCLC.
- mPFS not reached for lorlatinib vs. 9.1 mos w/ crizotinib (HR:0.19)
- 7yr PFS 55% w/ lorlatinib vs. 3%
- Gr 3/4 AEs: 77% vs. 57% (given such a profound benefit, focus now should be on AEs)
OptiTROP-Lung05 (China only study): PhIII, Sacituzumab Tirumotecan + Pembro vs. Pembro in TPS ≥ 1% mNSCLC 1L:
- ORR: 70.2% vs. 42%
- PFS HR in TPS 1-49: 0.28
- PFS HR in TPS ≥ 50%: 0.47
- AEs Gr ≥ 3 w/ sac-TMT: Neutropenia (17%), anemia (9%), & stomatitis (55%)
WU-KONG28: PhIII, Sunvozertinib vs. Chemo in 1L EGFR Exon 20 insertion mNSCLC:
- mPFS: 10.3mos vs. 7.5mos
- ORR: 58.9% vs. 31.1%
- AEs Gr ≥ 3 75.5% vs. 56.7% ( Cr, diarrhea, and anemia)
- Sunvozertinib was initially US FDA in 2L last year (2025)
EV-302 (3.5yrs update): PhIII, Pembro + Enfortumab in 1L metastatic bladder Ca (current SoC given doubling of OS)
- mOS 33.6mos vs. 15.9mos (HR: 0.53)
- Post EV+P, 20.7% had response to platinum chemo at the time of progression
- In responders, CR: 45.1% vs. 32.8%
MajesTEC-9: PhIII, Teclistamab vs. PVd (Pom + Bortezomib + Dex) or Kd (Carfilzomib + Dex) in refractory/relapse myeloma
- At 18mos, PFS: 70% vs. 27%
- OS w/ Tec (HR: 0.60) – Gr 3/4 AEs: 85% vs. 76%
- Tec based Rx in 2L now SoC
SUCCESSOR-2: PhIII, Mezigdomide (CELMoD) + Carfilzomib + Dex (MeziKd) vs. Kd in refractory/relapse myeloma
- At 18mos, PFS: 70% vs. 27%
- OS w/ Tec (HR: 0.60) – Gr 3/4 AEs: 85% vs. 76%
- Non CART or BsAb in 2L”
Other articles about Oncology Brothers on OncoDaily.
